Prognostic Value of Histone Acetyl Transferase 1 (HAT-1) and Inflammatory Signatures in Pancreatic Cancer

• Published in: Current Issues in Molecular Biology Vol. 46; no. 5; pp. 3839 - 3865
• Main Authors: Ortega, Miguel A, Jiménez-Álvarez, Laura, Fraile-Martinez, Oscar, Garcia-Montero, Cielo, Guijarro, Luis G, Pekarek, Leonel, Barrena-Blázquez, Silvestra, Asúnsolo, Ángel, López-González, Laura, Toledo-Lobo, María Del Val, Álvarez-Mon, Melchor, Saez, Miguel A, Gutiérrez-Calvo, Alberto, Díaz-Pedrero, Raúl
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.05.2024
• Subjects: Analysis; Cancer; DNA binding proteins; Epigenetic inheritance; Gastrointestinal diseases; Health aspects; histone acetyl transferase 1 (HAT-1); Histones; Immunohistochemistry; Inflammation; interleukin 10 (IL-10); Interleukins; Mortality; Oncology, Experimental; Pancreatic cancer; pancreatic ductal adenocarcinoma (PDAC); Prognosis; prognostic biomarkers; Protein binding; Spain; Type 2 diabetes; Spain; prognostic biomarkers; pancreatic ductal adenocarcinoma (PDAC); interleukin 10 (IL-10); histone acetyl transferase 1 (HAT-1)
• ISSN: 1467-3045; 1467-3037; 1467-3045
• DOI: 10.3390/cimb46050239

Pancreatic cancer is a type of gastrointestinal tumor with a growing incidence and mortality worldwide. Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of cases, and late-stage diagnosis is common, leading to a 5-year survival rate of less than 10% in high-income countries. The use of biomarkers has different proven translational applications, facilitating early diagnosis, accurate prognosis and identification of potential therapeutic targets. Several studies have shown a correlation between the tissue expression levels of various molecules, measured through immunohistochemistry (IHC), and survival rates in PDAC. Following the hallmarks of cancer, epigenetic and metabolic reprogramming, together with immune evasion and tumor-promoted inflammation, plays a critical role in cancer initiation and development. In this study, we aim to explore via IHC and Kaplan-Meier analyses the prognostic value of various epigenetic-related markers (histones 3 and 4 (H3/H4), histone acetyl transferase 1 (HAT-1), Anti-Silencing Function 1 protein (ASF1), Nuclear Autoantigenic Sperm Protein (NASP), Retinol Binding Protein 7 (RBBP7), importin 4 (IPO4) and IPO5), metabolic regulators (Phosphoglycerate mutase (PGAM)) and inflammatory mediators (allograft inflammatory factor 1 (AIF-1), interleukin 10 (IL-10), IL-12A and IL-18) in patients with PDAC. Also, through a correlation analysis, we have explored the possible interconnections in the expression levels of these molecules. Our results show that higher expression levels of these molecules are directly associated with poorer survival rates in PDAC patients, except in the case of IL-10, which shows an inverse association with mortality. HAT1 was the molecule more clearly associated with mortality, with a hazard risk of 21.74. The correlogram demonstrates an important correlation between almost all molecules studied (except in the case of IL-18), highlighting potential interactions between these molecules. Overall, our study demonstrates the relevance of including different markers from IHC techniques in order to identify unexplored molecules to develop more accurate prognosis methods and possible targeted therapies. Additionally, our correlation analysis reveals potential interactions among these markers, offering insights into PDAC's pathogenesis and paving the way for targeted therapies tailored to individual patient profiles. Future studies should be conducted to confirm the prognostic value of these components in PDAC in a broader sample size, as well as to evaluate the possible biological networks connecting them.